GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Does Cell Source Change Treatment Risks?

Yes. Cell source changes some treatment risks, but neither your own cells nor donor cells are always safer. Your own cells avoid exposure to another person’s cells, but collecting and processing them can still cause harm. Donor cells add donor-screening and immune-compatibility questions. In blood-forming stem cell transplantation, donor cells can cause graft-versus-host disease (GVHD), in which donor immune cells attack the recipient’s tissues. That transplant risk should not be applied to every donor-derived cell product.Stem cell transplant

Autologous means cells collected from the person receiving treatment; allogeneic means cells from another person. These labels describe whose cells are used, not whether the treatment works. Japan’s PMDA review index includes both types, such as autologous bone marrow-derived Stemirac and allogeneic bone marrow-derived Temcell. Stemirac’s original 2018 approval was conditional and time-limited. Each product has its own indication and evidence; approval is not a blanket endorsement of a cell source.0004

Does Cell Source Change Treatment Risks?

How your own cells and donor cells differ

Source-related differences in blood-forming stem cell transplantation for cancer
Risk or consideration Your own cells Donor cells
Immune compatibility The cells match the recipient. Matching matters; rejection and GVHD are concerns.
Cancer cells in the graft A small risk of returning cancer cells with the collected cells. Donor immune cells can attack remaining cancer cells, but can also attack healthy tissues.
Immune-system recovery Usually several months. Usually 1 to 2 years.

These are NCI’s descriptions of blood stem cell transplantation, often following high-dose chemotherapy or radiation. The recovery times refer to the immune system, not a guaranteed timetable for overall recovery. They do not describe routine mesenchymal stromal cell (MSC) infusions.Stem cell transplant The broader autologous versus allogeneic distinction is a starting point; the cell type and treatment setting determine which risks apply.

What donor-cell safety data actually show

Donor MSCs are not a blood stem cell graft

Temcell is a donor bone marrow-derived MSC product used to treat acute GVHD after blood stem cell transplantation. It is not the blood-forming graft that caused the GVHD. Its PMDA review discusses low expression of immune-recognition molecules and use without MHC matching, but that does not mean immune reactions are impossible.000215658.pdf This distinction matters when evaluating allogeneic cell therapy in Japan: one donor-derived product cannot stand in for all the others.

In PMDA’s Table 8.21, 6 of 39 patients (15.4%) in two Japanese Temcell studies had events classified as possibly associated with an immune response on the infusion day or the following day. Patients received preventive medication against allergic reactions. A separate placebo-controlled study reported 26 of 163 patients (16.0%) with Prochymal and 13 of 81 (16.0%) with placebo. These are specific event categories and study populations, not overall complication rates or proof that donor cells have no immune risk.000215658.pdf

The Japanese phase II/III study enrolled 25 patients with severe, steroid-refractory acute GVHD. During its 52-week study period, serious adverse events occurred in 22 patients and fatal events in 12. It was open-label and uncontrolled. Those outcomes cannot establish how much harm came from the MSC product rather than the underlying illness and other treatment; they also cannot predict risk for someone receiving cells for a different condition.000215658.pdf

Screening reduces infection risk without eliminating it

Donor eligibility and infectious-disease testing are separate from testing the finished cell product. The FDA publishes donor-screening test information for human cells and tissues in the United States; this is not a statement of Japanese requirements.Testing human cells tissues and cellular and tissue based product hctp donors relevant communicable Temcell’s 2015 review specifically noted that donors were not retested after the viral window period, when a recent infection may not yet be detectable. That is a finding about the reviewed manufacturing system, not a description of every donor-cell program today.000215658.pdf

Ask which infections the donor was tested for, when samples were taken, and how screening connects to the product you will receive. If traveling for care, request records in a language your home clinician can use and arrange follow-up before returning. CDC recommends obtaining overseas medical records and planning continuity of care; its medical-tourism guidance is not a safety rating of Japanese clinics.Medical tourism

Why your own cells are not risk-free

Autologous treatment avoids another person’s donor material, but the patient must supply the starting cells. Stemirac illustrates the distinction between collection risk and infusion risk. Its PMDA review describes anemia from peripheral blood collection and pain at the bone marrow puncture site. It also discusses potential infusion-related risks, including pulmonary embolism, thrombosis, hypersensitivity, infection, cancer relapse, and ectopic tissue formation. These potential risks are not all events observed in the trial.000231946.pdf

A practical check of the study documents

Following the patient numbers through the Stemirac report reveals an important detail: 17 people entered primary enrollment, 15 underwent bone marrow collection, and 13 actually received the product. The study reported no deaths or other serious adverse events, but it should not be described as 17 people receiving treatment without complications. Collection-related anemia occurred in two patients, and puncture-site pain in one. The treated group was small and selected, with traumatic cervical spinal cord injury; its main assessment was at 220 days after injury.000231946.pdf

For an offer you are considering, use the same document check: separate people enrolled, people treated, collection-related harms, infusion-related harms, and length of follow-up. A brochure saying “no serious events” leaves out information you need unless those details are available. The Stemirac findings cannot establish long-term safety for a different autologous product or for a different disease.

Timing is product-specific too. Stemirac’s original review aimed for bone marrow collection within 31 days after spinal cord injury. That is not a collection deadline for all autologous treatments. Ask what happens if collection is inadequate or a batch cannot be released, rather than assuming another collection or treatment will always be possible.000231946.pdf

Why tissue, manufacturing, and delivery matter

“Bone marrow-derived” does not identify a single treatment. Bone marrow can supply blood-forming stem cells for transplantation or starting material for an MSC product. Peripheral blood and umbilical cord blood are also sources for blood stem cell transplantation. Those uses should not be treated as interchangeable with MSC therapy.Stem cell transplant

Processing introduces another set of questions. Stemirac’s review describes controls addressing variable starting material, as well as product tests including sterility and endotoxins. Ask for the product’s actual release criteria and traceability records, not just a claim that the cells were processed in a cell processing center. A facility description alone does not establish the quality of the batch intended for you.000231946.pdf

Pluripotent-cell-derived products raise different questions again. PMDA’s AMCHEPRY review, for an iPS cell-derived neural progenitor product for a defined Parkinson’s disease population, evaluates residual undifferentiated cells and tumor or teratoma formation. The report describes mouse safety studies and conditional, time-limited approval. Animal findings cannot establish zero long-term human tumor risk or prove human benefit.000281617.pdf

The route also changes what clinicians must monitor. Stemirac’s intravenous-use review highlights clotting risks, infusion rate, vital-sign monitoring, and access to emergency care. These concerns do not disappear because the cells are autologous.000231946.pdf There is no sound basis for ranking bone marrow, fat, cord-derived, or iPS-derived products by source alone when their indications, processing, doses, and delivery methods differ.

What Japanese safety orders can tell you

On March 13, 2026, MHLW issued an emergency order after a patient deteriorated during administration of an autologous adipose-derived MSC intervention for chronic pain in Tokyo and subsequently died. The cause was unresolved when the order was issued. The action covered the clinic’s specified treatment and related provision, as well as specified manufacturing at JASC’s Kyoto facility; the notice also identified a Korean facility involved in manufacturing. It did not establish that all autologous cells were unsafe.Newpage_71555

A separate MHLW order dated April 21, 2026, described at least five patients who developed chills, fever, nausea, or other symptoms after treatment at a Fukuoka clinic on May 12 or 13, 2023; at least one later required hospitalization. The notice documented failures to report and investigate the events, continued treatment, and inadequate independent clinical judgment about patient eligibility and cell dose. These were specific oversight findings, not a head-to-head comparison of cell sources.Newpage_72690

These notices support practical questions about reporting, manufacturing responsibility, and who makes treatment decisions. They provide no denominator from which to calculate a general complication rate. The dates above distinguish the regulatory announcements from the events they describe; they are not claims about the providers’ current operating status.

What to request before deciding

Ask the treating clinician for written answers, not only a description such as “your own cells” or “young donor cells.”

  • Product and source: the exact product or preparation, cell type, tissue source, manufacturer, and whether it is autologous or allogeneic.
  • Clinical match: human evidence for your condition and disease stage, with numbers treated, comparator groups, adverse events, and follow-up duration.
  • Screening and quality: applicable donor tests, release criteria, batch identification, and a clear link between the records and your treatment.
  • Delivery: dose, route, schedule, collection requirements, and an explanation of why these are appropriate for you.
  • Aftercare: who handles complications, where emergency care is available, how events are reported, and who follows you after you return home.

Use the proposed treatment process to identify when those records will be supplied. Discuss indications and contraindications with the clinician rather than treating a source label as evidence of suitability.

Also ask whether the offer is an approved product used within its indication, a conditional approval, a clinical study, or a private-clinic service under a provision plan. A jRCT entry can help locate a study or plan; registration itself does not demonstrate efficacy.En top Japan’s regenerative medicine provision-plan framework is distinct from product marketing approval. Filing a plan does not establish that a treatment works.Index

Still weighing your own cells against donor cells?

Bring the product name, source, and dose you were offered. We can go through what those details mean before you decide.

Ask about your options

Is one cell source safer overall?

There is no single safety ranking that covers all cell treatments. Your own cells avoid donor exposure but still require safe collection, processing, and administration. Donor products require appropriate screening and immune-risk assessment. The useful comparison is between named treatments for the same condition, with comparable patients, delivery methods, and follow-up—not between source labels alone.

This is a comparison of public medical and regulatory documents, not a report of treating patients or a substitute for an individual medical assessment. Review any proposed treatment with a qualified clinician familiar with your condition.